US FDA to Reconvene Experts' Meeting for Amylyx ALS Drug

The US Food and Drug Administration will reconvene a meeting of its outside experts to review Amylyx Pharmaceuticals' application for its amyotrophic lateral sclerosis treatment, the company said Tuesday.

Related Keywords

United States ,Canada ,Tanabe Pharma Radicava ,Institute For Clinical ,Drug Administration ,Reuters ,Amylyx Pharmaceutical ,Mitsubishi Tanabe Pharma ,Economic Review ,Muscular Atrophy ,Uscular Atrophies ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Drug Development ,Drug Discovery ,Drug Pipeline ,Drug Development Pipeline ,Amyotrophic Lateral Sclerosis ,Ls ,Lou Gehrigs Disease ,Maladie De Charcot ,Clinical Research ,Clinical Trials ,Linical Studies ,Pre Clinical Trial ,Double Blind Study ,Double Blind Studies ,